Brentuximab Vedotin (SGN-35), an antibody–drug conjugate for the treatment of CD30-positive malignancies

Bibliography

• Connors JM. State-of-the-art therapeutics: hodgkin's lymphoma. J Clin Oncol 2005;23:6400-8
   PubMed Web of Science ®Google Scholar
• Carde P, Johnson P. Principles of chemotherapy in Hodgkin lymphoma. In: Engert A, Horning SJ, editors. Hodgkin lymphoma: a comprehensive update on diagnostics and clinics. Springer-Verlag; Berlin Heidelberg: 2010. p. 141-61
   Google Scholar
• Canellos GP, Anderson JR, Propert KJ, Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84
   PubMed Web of Science ®Google Scholar
• Kuppers R, Yahalom J, Josting A. Advances in biology, diagnostics, and treatment of Hodgkin's disease. Biol Blood Marrow Transplant 2006;12:66-76
   PubMed Web of Science ®Google Scholar
• Meyer RM, Gospodarowicz MK, Connors JM, Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634-42
   PubMed Web of Science ®Google Scholar
• Horning SJ, Chao NJ, Negrin RS, High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801-13
   PubMed Web of Science ®Google Scholar
• Kleiner S, Kirsch A, Schwaner I, High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study. Bone Marrow Transplant 1997;20:953-9
   PubMed Web of Science ®Google Scholar
• Baker KS, Gordon BG, Gross TG, Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 1999;17:825-31
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-14
   PubMed Web of Science ®Google Scholar
• Horning S, Fanale M, de Vos S, Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort [abstract]. Ann Oncol 2008;19:iv120-1
   Google Scholar
• Martinez C, Canals C, Alessandrino E, Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT [abstract]. J Clin Oncol 2010;28:588s
   Google Scholar
• Sureda A, Constans M, Iriondo A, Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005;16:625-33
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Kewalramani T, Nimer SD, Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124:645-52
   PubMed Web of Science ®Google Scholar
• Jacobsen E. Anaplastic large-cell lymphoma, T-/null-cell type. Oncologist 2006;11:831-40
   PubMed Web of Science ®Google Scholar
• Tilly H, Gaulard P, Lepage E, Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 1997;90:3727-34
   PubMed Web of Science ®Google Scholar
• Filippa DA, Ladanyi M, Wollner N, CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease. Blood 1996;87:2905-17
   PubMed Web of Science ®Google Scholar
• Stein H, Foss HD, Durkop H, CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-95
   PubMed Web of Science ®Google Scholar
• Weisenburger DD, Anderson JR, Diebold J, Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project. Am J Hematol 2001;67:172-8
   PubMed Web of Science ®Google Scholar
• Delsol G, Falini B, Muller-Hermelink HK, Anaplastic large-cell lymphoma, ALK-positive. In: Swerdlow SH, Campo E, Harris NL, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. International Agency for Research on Cancer; Lyon, France: 2008. p. 312-16
   Google Scholar
• Savage KJ, Harris NL, Vose JM, ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-504
   PubMed Web of Science ®Google Scholar
• Savage KJ. Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematology Am Soc Hematol Educ Program 2005;267-77
   PubMedGoogle Scholar
• Savage KJ. Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2008;280-8
   PubMedGoogle Scholar
• Stain H, Delsol G, Pileri SA, Classical Hodgkin Lymphoma, Introduction. In: Swerdlow SH, Campo E, Harris NL, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. International Agency for Research on Cancer; Lyon, France: 2008. p. 326-9
   Google Scholar
• Mason DY, Harris NL, Delsol G, Anaplastic large-cell lymphoma, ALK-negative. In: Swerdlow SH, Campo E, Harris NL, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition. International Agency for Research on Cancer; Lyon, France: 2008. p. 317-19
   Google Scholar
• Stein H, Mason DY, Gerdes J, The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-58
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. International Agency for Research on Cancer; Lyon, France: 2008
   Google Scholar
• Falini B, Pileri S, Pizzolo G, CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85(1):14
   Web of Science ®Google Scholar
• Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol 2009;647:174-85
   PubMed Web of Science ®Google Scholar
• Al-Shamkhani A. The role of CD30 in the pathogenesis of haematopoietic malignancies. Curr Opin Pharmacol 2004;4:355-9
   PubMed Web of Science ®Google Scholar
• Gerber HP. Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. Biochem Pharmacol 2010;79:1544-52
   PubMed Web of Science ®Google Scholar
• Guo F, Sun A, Wang W, TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. Mol Immunol 2009;46:2441-8
   PubMed Web of Science ®Google Scholar
• Hirsch B, Hummel M, Bentink S, CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol 2008;172:510-20
   PubMed Web of Science ®Google Scholar
• Horie R, Higashihara M, Watanabe T. Hodgkin's lymphoma and CD30 signal transduction. Int J Hematol 2003;77:37-47
   PubMed Web of Science ®Google Scholar
• Wright CW, Rumble JM, Duckett CS. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem 2007;282:10252-62
   PubMed Web of Science ®Google Scholar
• Amakawa R, Hakem A, Kundig TM, Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996;84:551-62
   PubMed Web of Science ®Google Scholar
• Chiarle R, Podda A, Prolla G, CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol 1999;163:194-205
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65
   PubMed Web of Science ®Google Scholar
• Okeley NM, Miyamoto JB, Zhang X, Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010;16:888-97
   PubMed Web of Science ®Google Scholar
• Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235-44
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21
   PubMed Web of Science ®Google Scholar
• Seattle Genetics, Inc. ADCETRIS™ (brentuximab vedotin) for Injection. Full Prescribing Information 2011. Available from: www.adcetris.com/_pdf/ADCETRIS_PromoPI_20110825.pdf
   Google Scholar
• Bartlett N, Grove LE, Kennedy DA, Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: a case series [abstract]. J Clin Oncol 2010;28:8062
   Google Scholar
• Fanale M, Bartlett NL, Forero-Torres A, The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study [abstract]. Blood 2009;114:1068-9
   Web of Science ®Google Scholar
• Chen RW, Gopal AK, Smith SE, Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) [abstract]. J Clin Oncol 2011;29:8031
   Google Scholar
• Younes A, Gopal AK, Smith SE, Durable complete remissions in a pivotal phase 2 study of SGN-35 (brentuximab vedotin) in patients with relapsed or refractory Hodgkin lymphoma (HL) [abstract]. Ann Oncol 2011;22:iv138
   Google Scholar
• Pro B, Advani R, Brice P, Durable remissions with brentuximab vedotin (SGN-35): updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) [abstract]. J Clin Oncol 2011;29:8032
   Google Scholar
• Shustov AR, Advani R, Brice P, Durable remissions with SGN-35 (brentuximab vedotin): updated results of a phase 2 study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) [abstract]. Ann Oncol 2011;22:iv125
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86
   PubMed Web of Science ®Google Scholar
• Chen R, Gopal AK, Smith SE, Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma [abstract]. Blood 2010;116:128-9
   Web of Science ®Google Scholar
• Shustov AR, Advani R, Brice P, Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma [abstract]. Blood 2010;116:423-4
   Web of Science ®Google Scholar
• Advani R, Fanale M, Brice P, Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma [abstract]. Haematologica 2011;96:154
   Google Scholar
• Gopal AK, Ramchandren R, Berryman RB, Brentuximab vedotin (SGN-35) treatment in relapsed CD30-positive Hodgkin's lymphoma patients following allogeneic stem cell transplant: a multi-center case series [abstract]. Bone Marrow Transplant 2011;46:S1-S89
   PubMed Web of Science ®Google Scholar
• Sureda A, Robinson S, Canals C, Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:455-62
   PubMed Web of Science ®Google Scholar
• Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer 2011;11:73-81
   PubMed Web of Science ®Google Scholar
• Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008;6:455-67
   PubMedGoogle Scholar
• Seattle Genetics, Inc. Brentuximab vedotin (SGN-35). FDA Oncologic Drugs Advisory Committee (ODAC) briefing document (BLA 125399) 2011. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM262598.pdf
   Google Scholar
• Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA 2011;305:2320-6
   PubMed Web of Science ®Google Scholar
• Josting A, Schmitz N. Insights into 25 years of clinical trials of the GHSG: relapsed and refractory Hodgkin's disease. In: Diehl V, Josting A, editors. 25 years German Hodgkin Study Group. Urban & Voegel; Munich: 2004. p. 89-99
   Google Scholar
• Lee L, Wang L, Crump M. Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. Ann Oncol 2011;22:1392-403
   PubMed Web of Science ®Google Scholar
• Advani R, Forero-Torres A, Fanale M, Objective responses with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) who refused or were ineligible for autologous stem cell transplantation (ASCT) [abstract]. Haematologica 2011;96:219-20
   Google Scholar
• Hutchinson CB, Wang E. Primary mediastinal (thymic) large B-cell lymphoma: a short review with brief discussion of mediastinal gray zone lymphoma. Arch Pathol Lab Med 2011;135:394-8
   PubMed Web of Science ®Google Scholar
• Lau SK, Weiss LM, Chu PG. D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohistochemical study with KIT (CD117) and CD30. Mod Pathol 2007;20:320-5
   PubMed Web of Science ®Google Scholar
• Haque T, Chaggar T, Schafers J, Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases. J Med Virol 2011;83:311-16
   PubMed Web of Science ®Google Scholar
• Purdue MP, Lan Q, Martinez-Maza O, A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood 2009;114:2730-2
   PubMed Web of Science ®Google Scholar
• Vermeulen R, Saberi HF, Portengen L, Circulating soluble CD30 and future risk of lymphoma; evidence from two prospective studies in the general population. Cancer Epidemiol Biomarkers Prev 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27
   PubMed Web of Science ®Google Scholar
• Drugs@FDA. Adcetris highlights of prescribing information. Available from: http://www.accessdata.fda.gov
   Google Scholar